2025 Clinical Practice Guideline Update by the Infectious Diseases Society

of America on Histoplasmosis: Treatment of Asymptomatic Histoplasma

Pulmonary Nodules (Histoplasmomas) in Adults, Children, and Pregnant

People

John W. Baddley<sup>\*</sup>,<sup>1</sup> Joshua Wolf<sup>\*</sup>,<sup>2</sup> Monica I. Ardura,<sup>3</sup> Nevert Badreldin,<sup>4</sup> Nathan C. Bahr,<sup>5,6</sup> Karen Bloch,<sup>7</sup> Carol Kauffman,<sup>8</sup> Robert J. Lentz,<sup>9</sup> Rachel A. Miller,<sup>10</sup> Satish Mocherla,<sup>11</sup> Peter Pappas,<sup>12</sup> Michael Saccente,<sup>13</sup> Ilan Schwartz,<sup>10</sup> Kayla R. Stover,<sup>14</sup> Nathan P. Wiederhold,<sup>15,16</sup> Jennifer Loveless<sup>+</sup>,<sup>17</sup> Andrej Spec<sup>+</sup>,<sup>18</sup> Sandra R. Arnold<sup>+</sup>,<sup>19,20</sup>

\*These authors contributed equally to the manuscript. \*These authors contributed equally to the manuscript.

<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>2</sup>St. Jude Children's Research Hospital, Memphis, TN, USA, <sup>3</sup>Nationwide Children's Hospital, Columbus, OH, USA, <sup>4</sup>Department of Obstetrics & Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, <sup>5</sup>Division of Infectious Diseases, Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA, <sup>6</sup>Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA, <sup>7</sup>Vanderbilt University Medical Center, Nashville, TN, USA, <sup>8</sup>University of Michigan, Ann Arbor, MI, USA, <sup>9</sup>Division of Allergy, Pulmonary & Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, <sup>10</sup>Division of Infectious Diseases, Duke University, Durham, NC, USA, <sup>11</sup>UT Southwestern, Dallas, TX, USA, <sup>12</sup>University of Alabama at Birmingham, Birmingham, AL, USA, <sup>13</sup>University of Arkansas for Medical Sciences, Little Rock, AR, USA, <sup>14</sup>University of Mississippi, Jackson, MS, USA, <sup>15</sup>University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, <sup>16</sup>Fungus Testing Laboratory, San Antonio, TX, USA, <sup>17</sup>Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, <sup>18</sup>Washington University in St. Louis, St. Louis, MO, USA, <sup>19</sup>Le Bonheur Children's Hospital, Memphis, TN, USA, <sup>20</sup>University of Tennessee Health Science Center, Memphis, TN, USA

ABSTRACT. This paper is part of a larger clinical practice guideline on the management of

histoplasmosis in adults, children, and pregnant people, developed by the Infectious Diseases Society of

America. In this paper, the panel provides a recommendation for treatment of asymptomatic pulmonary

nodules. The panel's recommendation is based upon evidence derived from systematic literature reviews

and adheres to a standardized methodology for rating the certainty of evidence and strength of

recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and

Evaluation) approach.

Key words. histoplasmosis; histoplasmoma; asymptomatic pulmonary nodules; itraconazole; treatment; guideline

# In patients with asymptomatic, previously untreated *Histoplasma* pulmonary nodules (histoplasmomas), for which patients should antifungal treatment be initiated?

**Recommendation:** In adults and children with asymptomatic non-calcified pulmonary nodules related to histoplasmosis with no evidence of other active sites, or asymptomatic patients with known untreated prior infection, the panel suggests against routinely providing treatment for histoplasmosis to prevent reactivation *(conditional recommendation, very low certainty of evidence)*.

# Remark(s):

- In patients with elevated risk for disseminated/severe histoplasmosis (especially those with immunocompromising conditions that confer high and moderate risk according to Table 1), closely monitor for clinical/radiological change or consider treatment.
- Patients with only calcified pulmonary nodules should not be treated.
- Treatment of pregnant individuals should only be considered after carefully weighing the potential benefits vs. harms of treatment, ideally in consultation with a maternal fetal medicine specialist and an infectious diseases specialist, as these cases are rare, complex, and highly variable. If treatment is necessary, azoles should be avoided in the first trimester when possible and liposomal amphotericin B used instead.

## Table 1. Categories of Immunocompromise and Risk for Disseminated/Severe Histoplasmosis

Categories of immunocompromise represent a continuum rather than distinct categories. Conditions are categorized here as a guide; given limited evidence, this table is **not** exhaustive or exact.

High Moderate Low <sup>*</sup>
--------------------------------

Receiving corticosteroids: <sup>[1]</sup> $\geq 2 \text{ mg/kg/day of prednisone (or equivalent) for persons } \leq 10$ kg or $\geq 20 \text{ mg/day of prednisone}$ (or equivalent) for persons >10 kg for at least 2 weeks	Receiving corticosteroids: <sup>[1]</sup> 0.5-2 mg/kg/day of prednisone (or equivalent) for persons <10 kg or 5-20 mg/day of prednisone (or equivalent) for persons >10 kg for at least 4 weeks	Receiving corticosteroids: <sup>[1]</sup> <0.5 mg/kg/day of prednisone (or equivalent) for persons <10 kg or ≤5 mg/day of prednisone (or equivalent) for persons >10 kg for at least 4 weeks
Primary cellular immunodeficiency (e.g., SCID, autosomal dominant hyperIgE syndrome [AD HIES], interferon-gamma receptor/IL- 12 pathway defects)	Primary immunodeficiency (e.g., common variable immunodeficiency, NF-kappaB pathway defects [NEMO], chronic mucocutaneous candidiasis, X-linked hyper IgM syndrome, autosomal recessive HIES)	
Advanced or untreated HIV/AIDS (CD4 <200 cells/mm <sup>3</sup> ) <sup>† [2]</sup>	HIV (CD4 200-300 cells/mm <sup>3</sup> ) [3-12]	HIV (CD4 ≥300 cells/mm <sup>3</sup> ); VL undetectable <sup>[2]</sup>
Hematopoietic stem cell transplant within 100 days or receiving immunosuppressive therapy for graft vs. host disease	Hematopoietic stem cell transplant >100 days prior and no evidence of graft vs. host disease	
Chimeric antigen receptor (CAR) T-cell therapy within 90 days <sup>[13]</sup>	Hematologic malignancy Chimeric antigen receptor (CAR) T-cell therapy >90 days and resolved cytopenias <sup>[13]</sup>	
Solid organ transplant and treatment of rejection <sup>‡</sup>	Solid organ transplant recipient on maintenance immunosuppressive regimen <sup>‡</sup>	
Autoimmune and rheumatic diseases requiring treatment with biologic agents <sup>§</sup> , especially those that interfere with T cell function and granuloma formation <sup>[9,14-19]</sup>		Autoimmune and rheumatic diseases not requiring treatment
		General medical frailty, including but not limited to: Liver, kidney, lung disease, diabetes, malnutrition

\*The following conditions confer no known increased risk: sickle cell disease and other asplenia syndromes; antibody, complement, or neutrophil deficiencies.

<sup>†</sup>Severe immunocompromise in children  $\leq 5$  years of age is defined as CD4+T lymphocyte [CD4+] percentage <15%, and in individuals  $\geq 6$  years, CD4+percentage <15% and CD4+>200 lymphocytes/mm<sup>3</sup> [1].

<sup>‡</sup>Carefully consider drug-drug interactions (e.g., tacrolimus for Graft-versus-host disease [GVHD] prophylaxis).

<sup>§</sup>There are a variety of biologic agents with varying levels of immunosuppression. Serious infections have happened in patients receiving biologic response modifiers, including tuberculosis and disseminated infections caused by viruses, fungi, or bacteria. Frequently reported biologics associated with disseminated/severe histoplasmosis include: Tumor necrosis factor-alpha inhibitors (TNF-alpha

inhibitors, e.g., infliximab, etanercept, adalimumab); IL12/IL23 blockade (ustekinumab, risankizumab, guselkumab).

#### **INTRODUCTION**

This paper is part of a clinical practice guideline update on the treatment of pulmonary histoplasmosis in adults, children, and pregnant people, developed by the Infectious Diseases Society of America [20,21]. This recommendation replaces the previous recommendation on treatment of pulmonary nodules (histoplasmomas) [22]. The primary audience for this recommendation is clinicians seeing patients with asymptomatic *Histoplasma* pulmonary nodules, including primary care clinicians, infectious diseases physicians, pulmonologists, specialists prescribing biologic response modifiers and other immunosuppressive agents, and cardiothoracic surgeons.

Asymptomatic pulmonary histoplasmosis refers to evidence of recent onset or active infection (based on review of recent, prior imaging indicating new or progressive radiographic abnormality, detection of urine or serum *Histoplasma* antigen, detection of *Histoplasma* antibodies by complement fixation with high titer ( $\geq$ 1:32) or rising titer on sequential testing, or presence of H-band by immunodiffusion). The presence of calcifications in lymph nodes or pulmonary nodules almost always indicates residual healed disease.

# **METHODS**

The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach (Supplementary Figure 1) [23]. The recommendation has been endorsed by the Pediatric Infectious Diseases Society, the Society of Infectious Diseases Pharmacists, and the Mycoses Study Group Education and Research Consortium.

Strong recommendations, indicated by "the panel recommends," are made when the recommended course of action would apply to most people with few exceptions. Conditional

recommendations, indicated by "the panel suggests," are made when the suggested course of action would apply to the majority of people with many exceptions and shared decision-making is important.

A comprehensive literature search (through January 2024) was conducted as part of a systematic review. Key eligibility criteria at both the topic and clinical question levels guided the search and selection of studies for inclusion (Supplementary Figure 2). Eligibility criteria were expanded to include case series and case reports due to a lack of evidence. Included studies were summarized narratively and critically appraised according to the GRADE approach. An assessment of benefits and harms of care options informed the recommendations [23,24]. Details of the systematic review and guideline development processes are available in the Supplementary Material.

#### SUMMARY OF EVIDENCE

Twenty-one studies (including case series and case reports) that addressed efficacy of antifungal therapy of asymptomatic pulmonary nodules in adults and children were identified (Supplementary Table 1) [3-12,15-19,25-30]. Included studies reported on the outcomes of progression to disseminated disease or significant pulmonary disease, reactivation of latent disease, and possible predisposing factors (Supplementary Table 2). We did not find any studies addressing this question in pregnant people.

In a single-center study, Demkowicz, et al. retrospectively evaluated short-term (up to 12 months) outcomes for 62 patients with pulmonary granulomas diagnosed as histoplasmomas presenting in a *Histoplasma* endemic area [27]. Most (39/62) of these patients did not receive antifungal therapy and did not have reactivation identified at that institution within 12 months after diagnosis. This suggests that for many patients with incidentally diagnosed histoplasmomas, antifungal therapy is not required for prevention of short-term reactivation. However, there are important limitations to this study that leave areas of uncertainty: 1. Highly immunocompromised patients typically received antifungal therapy with the goal of preventing reactivation, so it is unclear whether these patients could safely be managed without therapy; 2. Long-term clinical follow-up was not performed, so patients who developed reactivation disease more than 1 year after diagnosis, with or without being immunocompromised, would

not have been identified; 3. The investigators only identified illnesses diagnosed at that institution, so reactivation presenting at another hospital would have been missed.

Twenty studies provided evidence of possible or probable reactivation of latent disease in at least 275 patients [3-12,15-19,25,26,28-30]. In these studies, similar limitations as noted for the Demkowicz study above apply.

Several studies noted various immunocompromising conditions as possible predisposing factors for reactivation [Table 2].

Study	Study type	Exposure	No. with likely reactivation	Age (years)	Reactivation of latent infection <sup>[31]</sup>	Comments
HIV infect	ion	•				
Antinori 2006	Case series	HIV	4	Adult	Probable	Presentation in lower incidence area (Milan, Italy); median 24 months since last travel to higher incidence area (range 1- 144 months)
Anderson 2010	Case series	HIV	27	27-55	Possible	Presentation in lower incidence area (Atlanta, USA); Insufficient data for recent travel to higher incidence area to determine whether likely reactivation or acute/subacute presentation
Ashbee 2008*	Survey- based case series	HIV	43	Mostly adults	Probable	Presentation in lower incidence area (Europe); no recent travel (25% >5 years since last likely exposure)
Bourgeoi s 2011**	Case series	HIV	4	42-70	Probable	Presentation in lower incidence area (Montpellier and Nîmes, France); no recent travel (>4 years) in 4/7 cases
Buitrago 2011*	Case series	HIV	29	22-54	Possible	Presentation in lower incidence area (Spain); insufficient data for recent travel to higher incidence area to determine whether likely reactivation or acute/subacute presentation
Choi 2019	Case report	HIV	1	50	Probable	Presentation in lower incidence area (California, USA); no travel to higher incidence area in >30 years
Gandhi 2015*	Case series	HIV	1	27-77	Possible	Presentation in lower incidence area (Pittsburgh, PA and New York, New York, USA); recent travel not specified

Table 2. Evidence for reactivation of latent histoplasmosis in immunocompromising conditions

Study	Study type	Exposure	No. with likely reactivation	Age (years)	Reactivation of latent infection <sup>[31]</sup>	Comments
Peigne 2011**	Case series	HIV	104	~39 with SD~9	Probable	Presentation in lower incidence area (France); no recent travel in >59% of cases
Martin- Iguacel 2014	Case report	HIV	1	30	Probable	Presentation in lower incidence area (Copenhagen, Denmark); no recent travel
Norman 2009	Case series	HIV	5	Adult	Probable	Presentation in lower incidence area (Madrid, Spain); 3/5 no travel within 5 years
Immunom	odulatory ag	gents				
Ashbee 2008	Survey- based case series	Corticosteroids	7	Mostly adults	Probable	Presentation in lower incidence area (Europe); no recent travel (25% >5 years since last likely exposure)
Gandhi 2015	Case series	Corticosteroids/ Azathioprine	1	27-77	Probable	Presentation in lower incidence area (Pittsburgh, PA and New York, New York, USA); recent travel not specified
Jain 2006	Case report	Infliximab	1	40	Probable	Presentation in lower incidence area (Fresno, CA, USA); no recent travel (5 years)
Lucey 2018	Case report	Corticosteroids/ Azathioprine	1	62	Possible	Presentation in lower incidence area (London, United Kingdom); most recent travel to higher incidence area 5 months prior
Prakash 2019	Case report	Ruxolitinib	1	51	Possible	Presentation in lower incidence area (San Diego, CA, USA); insufficient data for recent travel to higher incidence area to determine whether likely reactivation or acute/subacute presentation
Sani 2018	Case report	Infliximab (plus azathioprine)	1	44 years	Probable	Presentation in lower incidence area (Tucson, AZ, USA); no recent travel (> 1 year)
Wallis 2004	Case series from AERS database	TNF antagonists (Etanercept and Infliximab) plus other immunomodula tory agents	42 (39 infliximab; 3 etanercept)	Not provide d	Possible	Insufficient data to determine whether acute/subacute infection or reactivation
Other immunocompromising conditions						
Alamri 2021	Case report	Heart transplant	1	68	Possible	Presentation in lower incidence area (Riyadh, Saudi Arabia); no recent travel (>2 years) but heart donor from higher incidence area
Ashbee 2008	Survey- based	Malignancy	2	Mostly adults	Probable	Presentation in lower incidence area (Europe); no recent travel

Study	Study type	Exposure	No. with likely reactivation	Age (years)	Reactivation of latent infection <sup>[31]</sup>	Comments
	case series					(25% >5 years since last likely exposure)
Buitrago 2011	Case series	Malignancy	1	22-54	Possible	Presentation in lower incidence area (Spain); insufficient data for recent travel to higher incidence area to determine whether likely reactivation or acute/subacute presentation
Carmans 2020	Case report	Renal transplantation	1	63	Probable	Presentation in lower incidence area (Belgium); no recent travel (>20 years)
Chang 2022	Case report	Renal transplantation	1	16	Possible	Presentation in lower incidence area (Southern California); possible exposure in NYC 6 years prior
Garcia- Marron 2008	Case report	Excessive alcohol use	1	46	Probable	Presentation in lower incidence area (Asturias, Spain); no recent travel (>10 years)

\*Some studies provided data for multiple categories of immunocompromise; participant age range was typically not provided for each category, so the overall range is provided.

\*\*Two studies report data from overlapping regions and time periods, so some participants might appear in both studies.

The overall certainty of evidence for all outcomes assessed is very low due to risk of bias concerns (Supplementary Table 3), as well as imprecision due to small sample sizes and limited number of events [32-33]. Refer to the Supplementary Material for exact judgments affecting certainty of evidence for each outcome.

# **RATIONALE FOR RECOMMENDATION**

Most patients who have asymptomatic pulmonary nodules (histoplasmomas) do not require therapy. In many cases, histoplasmomas represent past or dormant infection. However, there is the possibility of reactivation of infection, worsening pulmonary disease or disseminated disease. Based on published reports, it is unclear which underlying host conditions or other factors may lead to reactivation (Table 1). This literature review supports that many reported patients with likely reactivation were immunocompromised. Moreover, the time to reactivation varies greatly and may occur decades after initial infection. In some patients, the risk of reactivation may be higher and treatment to prevent reactivation should be discussed thoroughly with the patient or caregivers. Although itraconazole is typically safe, it is important to consider potential adverse effects, drug-drug interactions or other associated issues (costs) related to prolonged therapy. The panel agrees that the overall balance of benefits and harms favors avoiding routine treatment of asymptomatic histoplasmomas.

#### **IMPLEMENTATION CONSIDERATIONS**

We did not identify any specific data on treatment of asymptomatic histoplasmomas in pregnant or pediatric patients, but it would be reasonable to apply these recommendations to these populations. Due to the potential prolonged time in which reactivation of histoplasmomas may occur, the potential effects of months or years of antifungal therapy, including toxicities, drug-drug interactions and costs must be thoroughly considered.

### **RESEARCH NEEDS**

Additional studies are needed on the incidence and timing of reactivation with and without antifungal treatment (including itraconazole and newer azoles) in various populations, especially in pregnant persons and children. To date, there are no studies available that compare treatment versus no treatment in patients with asymptomatic pulmonary nodules (histoplasmomas). The most relevant study, by Demkowicz and colleagues, evaluated 12-month outcomes for 62 patients with pulmonary granulomas diagnosed as histoplasmomas presenting in a *Histoplasma* endemic area [27]. Most of these patients did not receive antifungal therapy and did not develop reactivation disease within 12 months after diagnosis. Highly immunocompromised patients typically received antifungal therapy with the goal of preventing reactivation, so it is unclear whether these patients could safely be managed without therapy.

*Acknowledgments:* The expert panel would like to acknowledge the previous panel, under the leadership of L. Joseph Wheat, for their work on the previous iteration of this larger guideline. The panel would like to acknowledge the contributions of Elizabeth Kiscaden and Mary Beth McAteer, medical librarians, for the creation and execution of question-specific literature search(es). Rebecca Goldwater and Imani Amponsah provided project coordination. The panel would also like to acknowledge the following organizations and selected external reviewers for their review of the draft manuscript: PIDS and SIDP; Drs. David Andes, John Christenson, and Marisa Miceli; and Drs. Robin Colgrove and Clinton White on behalf of the Standards & Practice Guidelines Subcommittee.

Sandra Arnold and Andrej Spec are chair and vice chair, respectively, of the expert panel. John Baddley and Joshua Wolf served as clinical leads for the question addressed in this manuscript. Remaining panelists assisted with conception and design of the analysis, interpretation of data, drafting and revising the recommendation and manuscript, and final approval of the recommendation and manuscript to be published. Jennifer Loveless, methodologist, was responsible for general project management, organizing and presenting the data, and leading the panel according to the GRADE process.

**Disclaimer:** It is important to recognize that guidelines cannot always account for individual variation among patients. They are assessments of current scientific and clinical information provided as an educational service; are not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is drafted and when it is published or read); should not be considered inclusive of all proper methods of care, or as a statement of the standard of care; do not mandate any course of medical care; and are not intended to supplant clinician judgment with respect to particular patients or situations. Whether to follow guidelines and to what extent is voluntary, with the ultimate determination regarding their application to be made by the clinician in the light of each patient's individual circumstances. While IDSA makes every effort to present accurate, complete, and reliable information, these guidelines are presented "as is" without any warranty, either express or implied. IDSA (and its officers, directors, members, employees, and agents) assume no responsibility for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with these guidelines or reliance on the information presented.

The guidelines represent the proprietary and copyrighted property of IDSA. All rights reserved. No part of these guidelines may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of IDSA. Permission is granted to physicians and health care providers solely to copy and use the guidelines in their professional practices and clinical decision making. No license or permission is granted to any person or entity, and prior written authorization by IDSA is required to sell, distribute, or modify the guidelines, or to make derivative works of or incorporate the guidelines into any product, including, but not limited to, clinical decision support software or any other software product. Except for the permission granted above, any person or entity desiring to use the guidelines in any way must contact IDSA for approval in accordance with the terms and conditions of third-party use, in particular any use of the guidelines in any software product.

Financial support. This work was supported by the Infectious Diseases Society of America.

**Possible conflicts of interest.** Evaluation of relationships as potential conflicts of interest is determined by a review process. The assessment of disclosed relationships for possible COIs is based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The following panelists have scientific advisory/consultant roles related to the topic (i.e., manageable conflicts of interest): A. S. (vice chair) with Mayne and Scynexis, C. K. with Cidara Therapeutics (concluded) and Laboratoires SMB S. A. (concluded), K. S. with Cidara Therapeutics (concluded), N. W. with F2G (concluded). C. K. is Editor-in-Chief for UpToDate's Infectious Diseases sections, and J. B. is an editor for UpToDate's Fungal Infections section. The following panelists have research relationships related to the topic: A. S. (vice chair) with Astellas; R. M. with Scynexis and F2G; P. P. with Mayne; N. W. with F2G, Scynexis, Mycovia (concluded), and Sfunga (concluded). No disclosures were reported for all other authors (the majority of panelists) including chair.

*Additional Information:* More detailed information on the analysis and development of recommendations is available in the Supplementary Material.

# REFERENCES

- Kroger A, Bahta L, Long S, Sanchez P. General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available at: <u>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html</u>. Accessed 06/16/2024.
- Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. 2024. Accessed 12/12/2024.

- 3. Antinori S, Magni C, Nebuloni M, et al. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine **2006**, 85(1):22-36.
- 4. Anderson AM, Mehta AK, Wang YF, et al. HIV-associated histoplasmosis in a nonendemic area of the United States during the HAART era: role of migration from endemic areas and lack of antiretroviral therapy. J Int Assoc Physicians AIDS Care **2010**, 9(5):296-300.
- 5. Ashbee HR, Evans EGV, Viviani MA, et al. Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol **2008**, 46(1): 57-65.
- 6. Bourgeois N, Douard-Enault C, Reynes J, et al. Seven imported histoplasmosis cases due to Histoplasma capsulatum var. capsulatum: From few weeks to more than three decades asymptomatic period. J Mycol Med 2011, 21(1):19-23.
- 7. Buitrago MJ, Bernal-Martinez L, Castelli MV, et al. Histoplasmosis and paracoccidioidomycosis in a nonendemic area: a review of cases and diagnosis. J Travel Med **2011**, 18(1):26-33.
- 8. Choi J, Nikoomanesh K, Uppal J, Wang, S. Progressive disseminated histoplasmosis with concomitant disseminated nontuberculous mycobacterial infection in a patient with AIDS from a nonendemic region (California). BMC Pulm Med **2019**, 19(1):46.
- 9. Gandhi V, Ulyanovskiy P, Epelbaum O. Update on the spectrum of histoplasmosis among Hispanic patients presenting to a New York City municipal hospital: a contemporary case series. Respir Med Case Rep 2015, 16:60-4.
- 10. Peigne V, Dromer F, Elie C, et al. Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras. Am J Trop Med Hyg **2011**, 85(5):934-41.
- 11. Martin-Iguacel R, Kurtzhals J, Jouvion G, Nielsen SD, Llibre JM. Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era: case report and literature review. Infection **2014**, 42(4):611-20.
- 12. Norman FF, Martin-Davila P, Fortun J, et al. Imported histoplasmosis: two distinct profiles in travelers and immigrants. J Travel Med **2009**, 16(4):258-62.
- 13. Shahid Z, Jain T, Dioverti V, et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther **2024**, 30(1):955-69.
- 14. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis **2010**, 50(1):85-92.
- 15. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med **2006**, 100(7):1291-3.
- 16. Lucey O, Carroll I, Bjorn T, Millar M. Reactivation of latent *Histoplasma* and disseminated cytomegalovirus in a returning traveller with ulcerative colitis. JMM Case Rep **2018**, 5(12):e005170.
- 17. Prakash K, Richman D. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib. BMC Infect Dis **2019**, 19(1):287.
- 18. Sani S, Bilal J, Varma E, et al. Not your typical Arizona granuloma: a case report of disseminated histoplasmosis. Am J Med **2018**, 131(9):e375-6.
- 19. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis **2004**, 38(9):1261-5.
- Arnold S, Spec A, Baddley JW, et al. 2025 clinical practice guideline update by the Infectious Diseases Society of America on histoplasmosis: treatment of asymptomatic Histoplasma pulmonary nodules (histoplasmomas) and mild or moderate acute pulmonary histoplasmosis in adults, children, and pregnant people. CID 2025;
- 21. Lentz RJ, Pappas P, Ardura, MI, et al. 2025 clinical practice guideline update by the Infectious Diseases Society of America on histoplasmosis: treatment of mild or moderate acute pulmonary histoplasmosis in adults, children, and pregnant people. CID **2025**;
- Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guideline for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2006, 45:807-25.
- 23. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ **2008**, 336: 924-6.
- Infectious Diseases Society of America. IDSA Handbook on Clinical Practice Guideline Development. Available at: https://www.idsociety.org/practice-guideline/clinical-practice-guidelines-developmenttraining-and-resources/. Accessed 01/03/2024.

- 25. Alamri M, Albarrag AM, Khogeer H, et al. Disseminated histoplasmosis in a heart transplant recipient from Saudi Arabia: a case report. J Infect Public Health **2021**, 14(8):1013-7.
- 26. Carmans L, Van Craenenbroeck A, Lagrou K, et al. Disseminated histoplasmosis in a kidney liver transplant patient from a non-endemic area: a diagnostic challenge. IDCases **2020**, 22:e00971.
- 27. Demkowicz, R, Procop GW. Clinical significance and histologic characterization of Histoplasma granulomas. Am J Clin Pathol **2021**, 155(4):581-7.
- Garcia-Marron M, Garcia-Garcia JM, Pajin-Collada M, et al. Chronic pulmonary histoplasmosis diagnosed in a nonimmunosuppresed patient 10 years after returning from an endemic area. Arch Bronconeumol 2008, 44(10):567-70.
- 29. Hess J, Fondell A, Fustino N, et al. Presentation and treatment of histoplasmosis in pediatric oncology patients: Case series and review of the literature. J Pediatr Hematol Oncol **2017**, 39(2):137-140.
- 30. Chang B, Saleh T, Wales C, et al. Case report: disseminated histoplasmosis in a renal transplant recipient from a non-endemic region. Front Pediatr 2022; 10:985475.
- 31. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis **2020**, 71(16): 1367-76.
- 32. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med **2013**; 158(4):280-6.
- 33. Sterne JAC, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ **2016**; 355:i4919.